The Wnt//β catenin signaling pathway drives tumor progression in HER2-positive breast cancers, which has been established by in vivo studies and plays a role in pathways involved in multiple resistance to standard antibreast cancer drugs [43]. Here, ERBB2 is linked to breast carcinoma.